Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

NCT03768505 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

169

Enrollment

INDUSTRY

Sponsor class

Stopped discontinuation of zandelisib program

Conditions

Follicular Lymphoma (FL)
Non Hodgkin Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Zandelisib (ME-401)

Sponsor

MEI Pharma, Inc.